#bpc-157
6 pieces tagged bpc-157.
Where the line isWhere research peptides sit on the WADA Prohibited ListFDA status and WADA status are different questions with different answers. Where BPC-157, TB-500, the GHRPs, the GHRH analogues, ipamorelin and Melanotan II sit on the 2026 Prohibited List, and what strict liability means.
Reading the paperworkMass spectrometry identity: what a one-dalton match provesESI and MALDI in plain terms, why a peptide shows up at several m/z values at once, monoisotopic against average mass, and a worked example on a stocked fifteen-residue peptide from its PubChem entry.
Where the line isFDA approved peptides in 2026: a status table with dates and sourcesWhich peptides have an FDA-approved product, which are investigational and which have neither, as of October 21, 2026. Every row carries a date and a primary source, with short answers for ipamorelin and BPC-157.
Where the line isCategory 1, Category 2 and the 503A bulks list in 2026Twelve peptides left FDA's Category 2 in April, GHK-Cu went back into Category 1 in May, and an advisory committee voted in July. None of it put a peptide on the 503A bulks list. A dated tracker.
Where the line isIs BPC-157 legal? FDA status, Category 2 and WADA in 2026BPC-157 is not banned in US law, not FDA approved and not compoundable under 503A. Its Category 2 history, the July 2026 committee vote and WADA S0, each dated to its source, as of October 2026.
Where the line isCompounding pharmacy, outsourcing facility or research supplierA 503A pharmacy, a 503B outsourcing facility and a research supplier operate under three different sets of rules. What each one is, why a pharmacy cannot compound BPC-157 today, and why a research vial has no place in the other two chains.
Nothing here is medical advice. Everything on this site is supplied for laboratory research use only.